Bevacizumab biosimilar (Samsung Bioepis)

贝伐珠单抗生物类似药 (Samsung Bioepis)

Report date: 2022/03/11 15:56:08

Base Information

Drug NameBevacizumab biosimilar (Samsung Bioepis)
Drug Alias Name贝伐单抗生物仿制药 (Samsung Bioepis)贝伐珠单抗生物仿制药 (Samsung Bioepis)贝伐赛珠单抗生物仿制药(Samsung Bioepis)贝伐人源化单抗生物仿制药 (Samsung Bioepis)Aybintio +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/08/19
Country/TerritoryBelgiumUkraineTaiwan +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active Companies3sbio IncMerck & Co IncSamsung Bioepis Nl Bv +[4] 
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsLung Neoplasms

Other Information

ATC CodeL01XC07
Related LinksN/A